Multivariable analysis of response by patient characteristics significant in univariable analysis
| Characteristic . | Odds ratio . | 95% CI . | P . |
|---|---|---|---|
| Cumulative fludarabine AUC, mg × h/L | 0.81 | 0.56-1.21 | .26 |
| Race* | .019 | ||
| Black/Hispanic | Ref | ||
| White | 5.28 | 1.37-25.7 | |
| Preinfusion disease burden | <.001 | ||
| None or low | Ref | ||
| High | 0.06 | 0.00-0.32 | |
| Prior CD19-directed therapy | .007 | ||
| No | Ref | ||
| Yes | 0.16 | 0.04-0.60 |
| Characteristic . | Odds ratio . | 95% CI . | P . |
|---|---|---|---|
| Cumulative fludarabine AUC, mg × h/L | 0.81 | 0.56-1.21 | .26 |
| Race* | .019 | ||
| Black/Hispanic | Ref | ||
| White | 5.28 | 1.37-25.7 | |
| Preinfusion disease burden | <.001 | ||
| None or low | Ref | ||
| High | 0.06 | 0.00-0.32 | |
| Prior CD19-directed therapy | .007 | ||
| No | Ref | ||
| Yes | 0.16 | 0.04-0.60 |
Ref, reference.
No events were observed in the other race groups.